Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): A randomised trial

The Lancet

Volumn 384, Issue 9955, 2014, Pages 1684-1690

  Friend, Peter ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK VIRUS INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HLA SYSTEM; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CHEMICALLY INDUCED; GRAFT REJECTION; PROCEDURES;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTIONS; RECOMBINANT FUSION PROTEINS;

EID: 84920877216     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61095-3     Document Type: Article

References (23)

1. HU Meier-Kriesche, JD Schold, B Kaplan Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4 2004 1289 1295
2. RA Wolfe, VB Ashby, EL Milford et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant N Engl J Med 341 1999 1725 1730
3. M Wyld, RL Morton, A Hayen, K Howard, AC Webster A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments PLoS Med 9 2012 e1001307
4. The Canadian Multicentre Transplant Study Group A randomized clinical trial of cyclosporine in cadaveric renal transplantation N Engl J Med 309 1983 809 815
5. BJ Nankivell, RJ Borrows, CL Fung, PJ O'Connell, RD Allen, JR Chapman The natural history of chronic allograft nephropathy N Engl J Med 349 2003 2326 2333
6. H Ekberg Calcineurin inhibitor sparing in renal transplantation Transplantation 86 2008 761 767
7. G Hale, S Bright, G Chumbley et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement Blood 62 1983 873 882
8. RD Morgan, JM O'Callaghan, SR Knight, PJ Morris Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis Transplantation 93 2012 1179 1199
9. MJ Hanaway, ES Woodle, S Mulgaonkar et al. Alemtuzumab induction in renal transplantation N Engl J Med 364 2011 1909 1919
10. R Haynes, C Baigent, P Harden et al. Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol Transplantation Res 2 2013 7
11. SJ Pocock, R Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
12. RJ Johnson, SV Fuggle, L Mumford et al. A New UK 2006 National Kidney Allocation Scheme for deceased heart-beating donor kidneys Transplantation 89 2010 387 394
13. KF Schulz, I Chalmers, RJ Hayes, DG Altman Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials J Am Med Assoc 273 1995 408 412
14. R Peto, MC Pike, P Armitage et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design Br J Cancer 34 1976 585 612
15. R Peto, MC Pike, P Armitage et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples Br J Cancer 35 1977 1 39
16. DR Cox Regression Models and Life-Tables J Royal Stat Soc Series B (Methodological) 34 1972 187 220
17. M Haas, B Sis, LC Racusen et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions Am J Transplant 14 2014 272 283
18. J Pascual, J Pirsch, J Torrealba et al. Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction Am J Transplant 8 suppl 2 2008 237
19. M Todeschini, M Cortinovis, N Perico et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development J Immunol 191 2013 2818 2828
20. G Opelz, B Döhler Influence of time of rejection on long-term graft survival in renal transplantation Transplantation 85 2008 661 666
21. S Shabir, JM Halimi, A Cherukuri et al. Predicting 5-year risk of kidney transplant failure: a prediction instrument using data available at 1 year posttransplantation Am J Kid Dis 63 2014 643 651
22. N Theodoropoulos, E Wang, S Penugonda et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation Am J Transplant 13 2013 197 206
23. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients Am J Transplant 9 suppl 3 2009 1 157